and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Termination of a Material Definitive Agreement. On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate the Company’s lease for approximately 94,046 rentable square feet at 33498 Central Avenue, Union City, California 94587. The space served as the Company’s Genetic Medicines Manufacturing Center (the “GMMC Facility”), which the Company decommissioned in 2025 to reduce costs. Closure of the GMMC Facil…

Chief Financial Officer — Eric Hyllengren: The company hired a new Chief Financial Officer.

The filing describes amendments to the equity incentive plan, not a management change.

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition. On March 11, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished in this

Entry into a Material Definitive Agreement. Collaboration Agreement On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”), pursuant to which the parties agreed to a research collaboration to discover and validate novel gene targets for the potential treatment of cardiovascular disease. The Company and Alnylam will nominate an aggregate of 15 targets, align on which targe…

The filing describes an amendment to the equity incentive plan, which is not a management change.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 28, 2026, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026, the Company did not meet the minimu…

Director — David Goeddel: Dr. David Goeddel resigned from the board of directors due to retirement.

Entry into a Material Definitive Agreement. On December 11, 2025, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in a firm commitment underwritten public offering (the “Offering”) of 50,000,000 units (the “Units”), at a public offering price of $1…

Results of Operations and Financial Condition. On November 10, 2025, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this

Results of Operations and Financial Condition. On August 6, 2025, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 15, 2025, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between March 3, 2025, through April 12, 2025, the Company did not meet the minimum bid pr…

Costs Associated with Exit or Disposal Activities. On March 27, 2025, Tenaya Therapeutics, Inc. (“Tenaya”) approved the implementation of a restructuring plan (the “Restructuring Plan”) to further focus company resources on generating data from MyPEAK TM -1, evaluating TN-201 as a gene therapy treatment for Myosin Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy, and RIDGE TM -1, evaluating TN-401 as a gene therapy treatment for plakophilin-2 (PKP2)-associated arrhythmogenic…

Results of Operations and Financial Condition. On March 10, 2025, Tenaya Therapeutics, Inc. (“Tenaya or the “Company”) issued a press release announcing Tenaya’s financial results for the quarter and the year ended December 31, 2024 (“the Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this

Entry into a Material Definitive Agreement. On March 3, 2025, Tenaya Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Piper Sandler & Co., as representatives (the “Representatives”) of the underwriters listed therein (the “Underwriters”), relating to the issuance and sale in a firm commitment underwritten public offering (the “Offering”) of 75,000,000 units (the “Units”), at a public offering price of $0.70…

Other Information. Effective March 3, 2025, the Company suspended and terminated the prospectus (the “ATM Prospectus”) related to the Common Stock issuable pursuant to the terms of a sales agreement, dated August 10, 2022, by and between the Company and Leerink Partners LLC (the “Sales Agreement”). As a result, the Company will not make any sales of the Company’s securities pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or a new registration statement…

Faraz Ali: The repricing of underwater stock options for the CEO to retain and motivate him.

The company repriced underwater stock options to retain and motivate employees.

Senior Vice President, Accounting and Financial Operations (SVP, AFO) and Interim Principal Accounting Officer (Interim PAO) — Ms. Chihiro Saito: Ms. Saito resigned to pursue another opportunity.

Results of Operations and Financial Condition. On November 6, 2024, Tenaya Therapeutics, Inc. (“Tenaya or the “Company”) issued a press release announcing Tenaya’s financial results for the quarter ended September 30, 2024 (“the Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this

Director — Karah Parschauer: Karah Parschauer was reappointed as a Class II director to more evenly distribute Board membership among the three classes of directors.

Interim Principal Financial Officer (PFO) and Interim Principal Accounting Officer (PAO) — Faraz Ali and Chihiro Saito: Ms. Leone Patterson has ceased her roles as Chief Financial and Business Officer, Principal Financial Officer (PFO), and Principal Accounting Officer (PAO). Faraz Ali will serve as Interim PFO while Chihiro Saito will assume the role of Interim PAO.